Cargando…

Targeting the Hippo Pathway for Breast Cancer Therapy

Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently the Hippo pathway is emerging as a tumor suppressor pathway with its four core components that regulate downstream t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Liqing, Yang, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266939/
https://www.ncbi.nlm.nih.gov/pubmed/30400599
http://dx.doi.org/10.3390/cancers10110422
_version_ 1783375951649832960
author Wu, Liqing
Yang, Xiaolong
author_facet Wu, Liqing
Yang, Xiaolong
author_sort Wu, Liqing
collection PubMed
description Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently the Hippo pathway is emerging as a tumor suppressor pathway with its four core components that regulate downstream transcriptional targets. In this review, we introduce the present targeted therapies of BC, and then discuss the roles of the Hippo pathway in BC. Finally, we summarize the evidence of the small molecule inhibitors that target the Hippo pathway, and then discuss the possibilities and future direction of the Hippo-targeted drugs for BC therapy.
format Online
Article
Text
id pubmed-6266939
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62669392018-12-03 Targeting the Hippo Pathway for Breast Cancer Therapy Wu, Liqing Yang, Xiaolong Cancers (Basel) Review Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently the Hippo pathway is emerging as a tumor suppressor pathway with its four core components that regulate downstream transcriptional targets. In this review, we introduce the present targeted therapies of BC, and then discuss the roles of the Hippo pathway in BC. Finally, we summarize the evidence of the small molecule inhibitors that target the Hippo pathway, and then discuss the possibilities and future direction of the Hippo-targeted drugs for BC therapy. MDPI 2018-11-05 /pmc/articles/PMC6266939/ /pubmed/30400599 http://dx.doi.org/10.3390/cancers10110422 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wu, Liqing
Yang, Xiaolong
Targeting the Hippo Pathway for Breast Cancer Therapy
title Targeting the Hippo Pathway for Breast Cancer Therapy
title_full Targeting the Hippo Pathway for Breast Cancer Therapy
title_fullStr Targeting the Hippo Pathway for Breast Cancer Therapy
title_full_unstemmed Targeting the Hippo Pathway for Breast Cancer Therapy
title_short Targeting the Hippo Pathway for Breast Cancer Therapy
title_sort targeting the hippo pathway for breast cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266939/
https://www.ncbi.nlm.nih.gov/pubmed/30400599
http://dx.doi.org/10.3390/cancers10110422
work_keys_str_mv AT wuliqing targetingthehippopathwayforbreastcancertherapy
AT yangxiaolong targetingthehippopathwayforbreastcancertherapy